Amma Asare, MD, PhD, discusses the elevated risk of therapy-related myeloid neoplasms or secondary leukemias in gynecologic cancers after a PARP inhibitor.
Amma Asare, MD, PhD
Advertisement
Articles by Amma Asare, MD, PhD
Amma Asare, MD, PhD on the use of AI for predicting PFS in ovarian cancer
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025
2
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma
3
FDA Grants Orphan Drug Designation to Gotistobart in Squamous NSCLC
4
WJ01024 Is Safe, Drives Durable Spleen Responses in R/R Myelofibrosis
5